中华老字号医药上市公司经营绩效研究
发布时间：2018-12-14 04:42
【摘要】：目的： 中医药老字号是我国文明历史的智慧结晶,是民族中药工商业百年沉淀的独特标识,具有深厚的历史印记与民族特色,已经成为了当今社会宝贵的物质和文化遗产,但在现实中,有大部分的中药老字号因为流失或经营不善而消失,能存活下来的中药老字号品牌较少,而有条件进入国内资本市场的中药老字号企业更是少之又少,本文研究的目的是探讨这些有着中药老字号辉煌品牌光环的上市公司的经营绩效与现状,研究其经营绩效的综合排名,取长补短,有利于提高中华老字号医药类上市公司的经营管理能力,弘扬中华文化,保护民族品牌。 方法： 本文通过文献分析法等对国内中华老字号、经营绩效的相关理论进行回顾与归纳,建立了十三个绩效指标的评价体系,并采用主成分分析法对国内A股资本市场上中药老字号企业2012年的经营数据进行分析得出其综合排名。 结果： 本文收集的19家研究样本的数据通过了KMO检验适合做主成分分析,得出2012年中华老字号医药类上市公司经营绩效的排名及各主成分排名,其中太安堂在2012年中经营绩效排名第一,开开实业排名第19；在盈利能力、偿债、营运、成长发展能力方面,排名第一的分别是云南白药、东阿阿胶、广州药业、太安堂。结论： 通过本文的研究,得出以下结论：有八家中华老字号医药上市公司的综合经营绩效明显高于其余几家；在2012年中,中华老字号医药类上市公司经营绩效整体较好；中华老字号医药类上市公司的综合效益差距不大；部分中华老字号在上市公司的运作中表现不佳。
[Abstract]:Objective: the traditional Chinese medicine brand is the wisdom crystallization of the civilization history of our country, is the unique symbol of the Chinese medicine industry and commerce precipitate for a hundred years, has the profound historical imprint and the national characteristic. It has become a valuable material and cultural heritage in today's society, but in reality, most of the old Chinese medicine brands have disappeared because of loss or poor management, and there are fewer brands of old Chinese medicine brands that can survive. However, there are few traditional Chinese medicine enterprises which have the condition to enter the domestic capital market. The purpose of this paper is to discuss the management performance and present situation of these listed companies with the glorious brand of traditional Chinese medicine. To study the comprehensive ranking of its management performance and to learn from each other is helpful to improve the management and management ability of the listed Chinese medicine companies, to carry forward the Chinese culture and to protect the national brands. Methods: based on the literature analysis method, this paper reviews and summarizes the relevant theories of China's old brand and management performance, and establishes the evaluation system of thirteen performance indicators. The main component analysis method is used to analyze the management data of the traditional Chinese medicine enterprises in the domestic A share capital market in 2012, and the comprehensive ranking is obtained. Results: the data of 19 research samples collected in this paper are suitable for principal component analysis through KMO test, and the ranking of operating performance and principal components of Chinese famous pharmaceutical listed companies in 2012 is obtained. Taiantang in 2012 in terms of operating performance ranked first, open industry ranked No. 19; In the profitability, debt service, operation, growth and development capacity, ranked first are Yunnan Baiyao, Donga Ejiao, Guangzhou Pharmaceutical Industry, Taiantang. Conclusion: through the research of this paper, the following conclusions can be drawn: there are eight famous Chinese medicine listed companies' comprehensive operating performance is obviously higher than the others, in the middle of 2012, the Chinese traditional medicine listed companies' overall operating performance is better; There is not much difference in the comprehensive benefit of the old Chinese medicine listed companies, and some of the old Chinese brands are not performing well in the operation of the listed companies.
【学位授予单位】：广州中医药大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：F272.5;F426.72
[Abstract]:Objective: the traditional Chinese medicine brand is the wisdom crystallization of the civilization history of our country, is the unique symbol of the Chinese medicine industry and commerce precipitate for a hundred years, has the profound historical imprint and the national characteristic. It has become a valuable material and cultural heritage in today's society, but in reality, most of the old Chinese medicine brands have disappeared because of loss or poor management, and there are fewer brands of old Chinese medicine brands that can survive. However, there are few traditional Chinese medicine enterprises which have the condition to enter the domestic capital market. The purpose of this paper is to discuss the management performance and present situation of these listed companies with the glorious brand of traditional Chinese medicine. To study the comprehensive ranking of its management performance and to learn from each other is helpful to improve the management and management ability of the listed Chinese medicine companies, to carry forward the Chinese culture and to protect the national brands. Methods: based on the literature analysis method, this paper reviews and summarizes the relevant theories of China's old brand and management performance, and establishes the evaluation system of thirteen performance indicators. The main component analysis method is used to analyze the management data of the traditional Chinese medicine enterprises in the domestic A share capital market in 2012, and the comprehensive ranking is obtained. Results: the data of 19 research samples collected in this paper are suitable for principal component analysis through KMO test, and the ranking of operating performance and principal components of Chinese famous pharmaceutical listed companies in 2012 is obtained. Taiantang in 2012 in terms of operating performance ranked first, open industry ranked No. 19; In the profitability, debt service, operation, growth and development capacity, ranked first are Yunnan Baiyao, Donga Ejiao, Guangzhou Pharmaceutical Industry, Taiantang. Conclusion: through the research of this paper, the following conclusions can be drawn: there are eight famous Chinese medicine listed companies' comprehensive operating performance is obviously higher than the others, in the middle of 2012, the Chinese traditional medicine listed companies' overall operating performance is better; There is not much difference in the comprehensive benefit of the old Chinese medicine listed companies, and some of the old Chinese brands are not performing well in the operation of the listed companies.
【学位授予单位】：广州中医药大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：F272.5;F426.72
【参考文献】
相关期刊论文 前10条
1 冷志明;“中华老字号”品牌发展滞后原因及其对策研究[J];北京工商大学学报(社会科学版);2004年01期
2 王海波;;企业绩效评价存在的问题及对策[J];财经界(学术版);2009年11期
3 茅静朦;;医药上市公司经营业绩评价体系设计[J];财会通讯;2012年35期
4 俞文强;朱春华;;基于SPSS下主成分分析中若干问题的总结[J];高等函授学报(自然科学版);2013年02期
5 杨帆;中华“老字号”的发展战略分析[J];环渤海经济w，
本文编号：2377944
本文链接：https://www.wllwen.com/jingjilunwen/gongyejingjilunwen/2377944.html
